Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q92564
UPID:
DCNL4_HUMAN
Alternative names:
DCUN1 domain-containing protein 4; Defective in cullin neddylation protein 1-like protein 4
Alternative UPACC:
Q92564; B4DH25; Q7Z3F3; Q7Z6B8
Background:
DCN1-like protein 4, also known as DCUN1 domain-containing protein 4 or Defective in cullin neddylation protein 1-like protein 4, plays a crucial role in the neddylation process. It facilitates the transfer of NEDD8, a ubiquitin-like molecule, to cullin proteins within the cullin-RING E3 ubiquitin ligases (CRLs). This transfer is essential for the activation of CRLs, which are involved in various cellular processes including protein degradation.
Therapeutic significance:
Understanding the role of DCN1-like protein 4 could open doors to potential therapeutic strategies. Its pivotal function in protein degradation pathways suggests that modulating its activity could influence cellular processes implicated in disease states.